• Je něco špatně v tomto záznamu ?

Expanding horizons of achondroplasia treatment: current options and future developments

B. Fafilek, M. Bosakova, P. Krejci

. 2022 ; 30 (4) : 535-544. [pub] 20211202

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019044

Activating mutations in the FGFR3 receptor tyrosine kinase lead to most prevalent form of genetic dwarfism in humans, the achondroplasia. Many features of the complex function of FGFR3 in growing skeleton were characterized, which facilitated identification of therapy targets, and drove progress toward treatment. In August 2021, the vosoritide was approved for treatment of achondroplasia, which is based on a stable variant of the C-natriuretic peptide. Other drugs may soon follow, as several conceptually different inhibitors of FGFR3 signaling progress through clinical trials. Here, we review the current achondroplasia therapeutics, describe their mechanisms, and illuminate motivations leading to their development. We also discuss perspectives of curing achondroplasia, and options for repurposing achondroplasia drugs for dwarfing conditions unrelated to FGFR3.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019044
003      
CZ-PrNML
005      
20220804135318.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.joca.2021.11.017 $2 doi
035    __
$a (PubMed)34864168
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Fafilek, B $u Department of Biology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic; Institute of Animal Physiology and Genetics of the CAS, 60200, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic
245    10
$a Expanding horizons of achondroplasia treatment: current options and future developments / $c B. Fafilek, M. Bosakova, P. Krejci
520    9_
$a Activating mutations in the FGFR3 receptor tyrosine kinase lead to most prevalent form of genetic dwarfism in humans, the achondroplasia. Many features of the complex function of FGFR3 in growing skeleton were characterized, which facilitated identification of therapy targets, and drove progress toward treatment. In August 2021, the vosoritide was approved for treatment of achondroplasia, which is based on a stable variant of the C-natriuretic peptide. Other drugs may soon follow, as several conceptually different inhibitors of FGFR3 signaling progress through clinical trials. Here, we review the current achondroplasia therapeutics, describe their mechanisms, and illuminate motivations leading to their development. We also discuss perspectives of curing achondroplasia, and options for repurposing achondroplasia drugs for dwarfing conditions unrelated to FGFR3.
650    12
$a achondroplazie $x farmakoterapie $x terapie $7 D000130
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a receptor fibroblastových růstových faktorů, typ 3 $x genetika $x metabolismus $7 D051498
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bosakova, M $u Department of Biology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic; Institute of Animal Physiology and Genetics of the CAS, 60200, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic
700    1_
$a Krejci, P $u Department of Biology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic; Institute of Animal Physiology and Genetics of the CAS, 60200, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic. Electronic address: krejcip@med.muni.cz
773    0_
$w MED00003657 $t Osteoarthritis and cartilage $x 1522-9653 $g Roč. 30, č. 4 (2022), s. 535-544
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34864168 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135312 $b ABA008
999    __
$a ok $b bmc $g 1822590 $s 1170287
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 30 $c 4 $d 535-544 $e 20211202 $i 1522-9653 $m Osteoarthritis and cartilage $n Osteoarthritis Cartilage $x MED00003657
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace